Lincoln National Corp Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

Lincoln National Corp bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,675 shares of the company’s stock, valued at approximately $301,000.

Several other institutional investors also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its position in Moderna by 89.9% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 6,443,409 shares of the company’s stock valued at $761,934,000 after purchasing an additional 3,051,035 shares during the period. Renaissance Technologies LLC increased its stake in Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares in the last quarter. Northern Trust Corp increased its stake in Moderna by 0.6% during the 1st quarter. Northern Trust Corp now owns 3,503,325 shares of the company’s stock valued at $603,483,000 after purchasing an additional 20,416 shares in the last quarter. Banque Pictet & Cie SA boosted its holdings in shares of Moderna by 1.9% in the 4th quarter. Banque Pictet & Cie SA now owns 3,081,437 shares of the company’s stock valued at $553,488,000 after acquiring an additional 57,256 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Moderna by 21.1% during the first quarter. Invesco Ltd. now owns 2,128,252 shares of the company’s stock worth $366,611,000 after buying an additional 371,311 shares in the last quarter. 63.11% of the stock is owned by hedge funds and other institutional investors.

Moderna Trading Up 1.5 %

NASDAQ MRNA opened at $133.77 on Wednesday. The firm has a 50 day simple moving average of $145.22 and a 200-day simple moving average of $164.93. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.26 and a current ratio of 3.46. Moderna, Inc. has a one year low of $115.03 and a one year high of $217.25. The firm has a market cap of $50.99 billion, a price-to-earnings ratio of 11.56 and a beta of 1.70.

Moderna (NASDAQ:MRNA – Get Rating) last issued its quarterly earnings results on Thursday, May 4th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.77) by $1.96. Moderna had a net margin of 31.77% and a return on equity of 25.87%. The company had revenue of $1.86 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the firm earned $8.58 earnings per share. The firm’s quarterly revenue was down 69.3% on a year-over-year basis. Equities research analysts anticipate that Moderna, Inc. will post -2.67 EPS for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the topic of several recent analyst reports. TD Cowen raised shares of Moderna from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $150.00 to $180.00 in a report on Monday, March 13th. JPMorgan Chase & Co. increased their price objective on shares of Moderna from $127.00 to $145.00 and gave the company a “neutral” rating in a report on Monday, April 10th. SVB Securities cut shares of Moderna from a “market perform” rating to an “underperform” rating and reduced their target price for the company from $111.00 to $93.00 in a research report on Friday, February 24th. Chardan Capital increased their target price on shares of Moderna from $191.00 to $208.00 and gave the company a “neutral” rating in a research report on Wednesday, January 18th. Finally, Cowen increased their target price on shares of Moderna from $130.00 to $150.00 and gave the company a “market perform” rating in a research report on Wednesday, January 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $179.13.

Insider Buying and Selling

In related news, President Stephen Hoge sold 245 shares of Moderna stock in a transaction that occurred on Friday, February 10th. The shares were sold at an average price of $163.90, for a total value of $40,155.50. Following the completion of the transaction, the president now owns 1,627,693 shares in the company, valued at $266,778,882.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Moderna news, President Stephen Hoge sold 245 shares of the firm’s stock in a transaction that occurred on Friday, February 10th. The shares were sold at an average price of $163.90, for a total transaction of $40,155.50. Following the sale, the president now owns 1,627,693 shares of the company’s stock, valued at $266,778,882.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $130.61, for a total transaction of $5,224,400.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $706,854,267.06. The disclosure for this sale can be found here. Insiders sold 432,337 shares of company stock worth $64,432,932 over the last 90 days. 15.70% of the stock is owned by insiders.

Moderna Company Profile

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.